Check out the Detailed Program! Learn More

Immunotherapy In Advanced Esophageal Squamous Cell Carcinoma

Advanced esophageal squamous cell carcinoma (ESCC) has historically been difficult to control because many patients present with metastatic or unresectable disease. Cytotoxic chemotherapy can reduce tumor burden, yet responses may be temporary and treatment tolerance can be limited by dysphagia, malnutrition, pain, and coexisting illness.

Immune checkpoint inhibitors have changed the treatment discussion. By blocking inhibitory signals involving PD-1, PD-L1, or CTLA-4, these medicines can restore antitumor T-cell activity. Their benefits are meaningful for selected patients, although response patterns, biomarker results, and toxicity risks require careful interpretation.

Treatment decisions should be based on pathology, disease extent, performance status, nutritional condition, organ function, and patient goals. Findings presented through specialist societies and international congresses such as ISDE 2021 continue to support multidisciplinary evaluation of complex esophageal disease.

Why Immunotherapy Matters In ESCC

ESCC develops in an immune environment shaped by chronic inflammation, tobacco and alcohol exposure, viral factors in some regions, and substantial genetic diversity. Tumor cells may exploit PD-1/PD-L1 signaling to suppress immune recognition. Checkpoint blockade interrupts that signal, allowing immune cells to attack malignant tissue.

The clinical value of immunotherapy differs from conventional chemotherapy. Some patients experience durable disease control after an early period of stable disease, while others progress quickly. Radiographic assessment therefore needs clinical context, especially when symptoms, inflammatory changes, or atypical response patterns complicate interpretation.

Evidence From First-Line Treatment

The strongest evidence for advanced disease supports combining a checkpoint inhibitor with platinum-based chemotherapy and a fluoropyrimidine. Trials such as KEYNOTE-590 and CheckMate 648 demonstrated improved outcomes in appropriate patients with advanced esophageal cancer, with particularly important benefits reported in ESCC and in groups defined by PD-L1 expression.

Nivolumab with chemotherapy, nivolumab plus ipilimumab, and pembrolizumab-based combinations may be considered depending on regional approvals, PD-L1 testing, contraindications, and available expertise. Treatment guidelines should be checked regularly because indications and preferred regimens continue to evolve.

Treatment approach Common clinical setting Important considerations
Checkpoint inhibitor plus chemotherapy Initial treatment for unresectable or metastatic ESCC Offers rapid cytoreduction from chemotherapy with potential immune durability
Checkpoint inhibitor alone Selected patients with biomarker support or chemotherapy intolerance May be better tolerated but can produce slower or less predictable tumor shrinkage
Dual checkpoint blockade Selected first-line patients in approved settings Can increase immune toxicity and requires careful patient selection
Later-line immunotherapy Disease progression after systemic treatment Benefit depends on prior therapy, PD-L1 status, and local authorization

Biomarkers And Patient Selection

PD-L1 testing is commonly reported using the combined positive score (CPS) or tumor proportion score (TPS), depending on the assay and treatment regimen. A higher score may enrich the population likely to benefit, but PD-L1 is an imperfect predictor. A low score does not always exclude benefit, and a high score cannot guarantee response.

Performance status, autoimmune disease, transplant history, uncontrolled infection, steroid dependence, and organ impairment should be reviewed before treatment. Severe malnutrition and dehydration can also affect tolerance. In older adults with several comorbidities, broader perioperative and supportive planning is valuable; discussions of surgical care for older patients illustrate why functional assessment should accompany disease-focused decisions.

Managing Immune-Related Toxicity

Immune-related adverse events can involve almost any organ. Common concerns include rash, diarrhea or colitis, thyroid dysfunction, hepatitis, pneumonitis, nephritis, and adrenal or pituitary inflammation. Symptoms may appear during treatment or weeks after the last dose, so patients need clear instructions for reporting new problems.

Management depends on severity and the affected organ. Treatment may involve holding immunotherapy, laboratory monitoring, specialist referral, corticosteroids, or other immunosuppressive therapy. Fever, shortness of breath, severe diarrhea, jaundice, confusion, and rapidly worsening weakness require urgent assessment because delayed recognition can result in serious complications.

Integrating Supportive And Local Care

Systemic therapy works best when paired with active symptom management. Dysphagia may require dietary modification, nutritional support, endoscopic intervention, or carefully selected stenting. Pain control, smoking cessation, psychosocial support, and early palliative care can improve quality of life alongside anticancer treatment.

Radiation therapy or surgery may have a role in selected situations, such as bleeding, obstruction, oligometastatic disease, or durable local control after systemic response. These decisions should be made by a team involving medical oncology, radiation oncology, gastroenterology, surgery, radiology, pathology, nutrition, and specialist nursing.

A Practical Treatment Framework

Before treatment begins, clinicians should confirm histology and stage, obtain baseline imaging, assess PD-L1 status where relevant, and document renal, hepatic, endocrine, and pulmonary function. Medication review is essential, particularly for corticosteroids and other immunosuppressants that may influence immune activation or toxicity management.

During therapy, response assessment should combine scans with swallowing function, weight, pain, nutritional intake, and performance status. Continuing treatment requires evidence of benefit and acceptable toxicity. Progression should prompt review of adherence, imaging timing, mixed response, and opportunities for clinical trials rather than an automatic assumption that every lesion represents treatment failure.

Priorities For Clinical Practice

  • Use pathology, staging, PD-L1 results, comorbidities, and patient preferences together rather than relying on one biomarker.
  • Discuss the expected benefits and limitations of immunotherapy before the first dose.
  • Establish baseline laboratory tests and educate patients about delayed immune-related adverse events.
  • Coordinate nutrition, dysphagia care, symptom control, and psychosocial support throughout treatment.
  • Reassess response and treatment goals at regular multidisciplinary meetings.

Immunotherapy has created durable treatment opportunities for some people with advanced ESCC, but its success depends on thoughtful selection, rapid toxicity management, and coordinated supportive care. Clinicians and learners can deepen their understanding through specialist congress resources, updated guidelines, and ongoing clinical research in esophageal oncology.

About ISDE

The ISDE is an international, multispecialty society devoted to the study of the esophagus in disease and in health that was founded in 1979. The aims of the ISDE are to promote the exchange of scientific and medical knowledge among specialists in the field, to maintain interchange with organizations and industries, and to encourage basic and clinical research in fields related to the esophagus. In order to promote the professional and educational development of individuals interested in the esophagus, the ISDE sponsors its own journal, international congresses, and other educational programs. The ISDE Secretariat was in Tokyo, Japan, from 1979 to 2004, and then resided in Los Angeles, California, from 2004 through 2010. Since 2010 the Secretariat has been in Vancouver, British Columbia, under the auspices of International Conferences Service, Ltd. The ISDE welcomes participation by existing members and encourages individuals who are professionally interested in the esophagus to become members. Benefits include reduced registration fees at our congresses and other educational offerings, restricted access to website content and member search capability, access to webcasts, reduced subscription rates for our journal, and the opportunity to help lead this organization into a position of leadership in the worldwide medical community.